Source: EqualOcean

Shanghai Fudan-zhangjiang: HK Stock Shanghai Fudan-Zhangjiang Back to SSE Star Market

Shanghai Fudan-Zhangjiang biopharmaceutical (1349:HKEX) eyes on capital from the Star Market to further boost its research and development projects.

Read full article »
Shanghai Fudan-zhangjiang's Competitors | Shanghai Fudan-zhangjiang's News | Shanghai Fudan-zhangjiang's Financials
Stay up-to-date with the latest news on Shanghai Fudan-zhangjiang
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
CEO Avatar

General Manager

Haibo Wang

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on Shanghai Fudan-zhangjiang